Fulcrum lays off majority of staff; Seres extends runway into 2027

Fulcrum Therapeutics cuts 84% of staff after halting sickle cell drug; Seres extends cash runway to Q1 2027 via $25M Nestlé deal.

Raccontata daendpoints.news